Loading clinical trials...
Loading clinical trials...
Pilot Study of the Feasibility and Safety of a Personalized Peptide Vaccine in Patients With Advanced Pancreatic Ductal Adenocarcinoma or Colorectal Adenocarcinoma
Conditions
Interventions
Imiquimod
Pembrolizumab
+4 more
Locations
1
United States
M D Anderson Cancer Center
Houston, Texas, United States
Start Date
May 11, 2016
Primary Completion Date
May 31, 2027
Completion Date
May 31, 2027
Last Updated
April 24, 2026
NCT06696768
NCT06445062
NCT04511039
NCT05334069
NCT01365169
NCT07165951
Lead Sponsor
M.D. Anderson Cancer Center
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions